5 results about "Lymphopoiesis" patented technology

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and / or NK cells. The methods can include inhibitory RNA molecule(s) and / or engineered signaling polypeptides that can include a lymphoproliferative element, and / or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and / or genetically modified T cells and / or NK cells are provided, such as, for example, those including riboswitches, MRB-CARS, recognition domains, and / or pH-modulating agents.

This invention relates to the field of biological vaccine technology, specifically disclosing a Mycobacterium tuberculosis Ag85B DNA vaccine, its preparation method, and its application. The HSV2gD signal peptide gene and the Rv1886c gene are linked between HindⅢ / Xbal on the vector pcDNA3.1+ to obtain the pcD-sRv1886c plasmid, which is the Mycobacterium tuberculosis Ag85B DNA vaccine. The pcD-sRv1886c recombinant plasmid of this invention, expressing Ag85B protein, can effectively induce CD4+ secretion of IFN-γ. + T and CD8 + T cells accounted for 2.03% and 1.05%, respectively. Furthermore, the expression of Ag85B protein by this plasmid could stimulate the proliferation of splenic lymphocytes, with a proliferation stimulation index of 5.02. The immune effect generated by the stimulation of Ag85B protein expressed by this plasmid had a significant killing effect on Mycobacterium tuberculosis H37Ra infection.

The invention relates to antibodies directed against CD127, the alpha chain of the interleukin 7 (IL-7) receptor IL-7R), and which have antagonist properties for IL-7-IL-7R interaction, may present cytotoxic activity against CD127 positive cells but do not increase the maturation of dendritic cells (DCs) induced by TSLP, a cytokine also using CD127 as part of its receptor. Alternatively, or in addition, these antibodies do not induce the internalization of CD127 and / or inhibit the IL7-induced internalization of CD127. According to another aspect of the invention antibodies are provided which recognize a human CD127 epitope comprising sequences from the 2b site of CD127, in particular the epitope comprising comprises the human CD127 sequences of domain D1 and of the 2b site of CD127, in particular the epitope comprises at least one sequence from D1 comprising SEQ ID No: 115 (in particular comprising SEQ ID No: 110) and / or SEQ ID No: 111 and / or a sequence from the 2b site comprising the sequence of SEQ ID No: 116 and optionally also comprises SEQ ID No: 117 (in particular comprises SEQ ID No: 111). The antibodies of the invention are suitable for use in order to remedy to a condition diagnosed in a human patient which results from pathogenesis related to lymphopoiesis, when IL-7 signalling pathways provide contribution to said pathogenesis, especially when an increase in the maturation, more precisely the upregulation of costimulatory molecules, of dendritic cells is undesirable.

Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.

The invention relates to the technical field of medicines and chemistry, and particularly discloses a medical application of a vertramine type isosteroid alkaloid zhebeisine with a 6 / 6 / 5 / 6 / 6 / 6 fused ring system, which is separated from a dry bulb of a liliaceae plant Fritilaria hupehensis Hsiao et K.C.Hsia, in preparation of an immunosuppressive drug, and a preparation method of the vertramine type isosteroid alkaloid zhebeisine with the 6 / 6 / 5 / 6 / 6 fused ring system, wherein the vertramine type isosteroid alkaloid zhebeisine has the advantages that the vertramine type isosteroid alkaloid zhebeisine with the 6 / 6 / 5 / 6 / 6 fused ring system is obtained; more specifically, the invention relates to an application in preparation of drugs having significant inhibitory activity on proliferation of T lymphocytes and B lymphocytes. The veratramine type isosteroid alkaloid disclosed by the invention has the advantages of low toxicity and high efficiency, and can be used for preparing immunosuppressive drugs aiming at organ transplantation and / or autoimmune diseases.